



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/966,783	09/28/2001	Stanko Bodnar	CRD-0967	5435

27777 7590 10/30/2006

PHILIP S. JOHNSON
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003

EXAMINER

CHORBAJI, MONZER R

ART UNIT	PAPER NUMBER
----------	--------------

1744

DATE MAILED: 10/30/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/966,783

Applicant(s)

BODNAR ET AL.

Examiner

MONZER R. CHORBAJI

Art Unit

1744

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 September 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-40 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-40 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 28 September 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- ☐ Notice of Informal Patent Application
- ☐ Other: _____

DETAILED ACTION

This non-final action is in response to the RCE/Amendment received on 09/09/2006

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Art Unit: 1744

4. Claims 1-10, 20, 21 and 28-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Muth et al (U.S.P.N. 5,472,702) in view of McGowan, Jr. (U.S.P.N. 5,749,203) and Mitchell (EP 0 568 310) as further evidenced by Sigma-Aldrich (biocompare.com Internet printout).

Regarding claims 1 and 20, Muth teaches the following: positioning packaged (col.1, lines 19-24, col.2, lines 24-26 and col.5, lines 5-9), drug coated medical device such that the drug contains an anti-proliferative agent (col.4, lines 40-42 and the specification on page 15 teaches that an example of anti-proliferative agents are antibiotics) in a sterilization chamber (col.7, line 38), increasing and maintaining the temperature in the sterilization chamber in the range from 25-35 degrees Celsius and the relative humidity in the range from 40%-85% for a predetermined time period (col.6, lines 43-46), injecting a sterilization agent at a predetermined concentration into the chamber and maintaining the temperature in the range from 25-35 degrees Celsius and the relative humidity in the range from 40%-85% for a predetermined time period (col.7, table, lines 54-59) and removing the sterilization agent from the chamber through a plurality of vacuum washes over another predetermined time period by maintaining the chamber at a temperature in the range of 30-40 degree Celsius (col.7, table, Exhaust, lines 66-67 and col.8, lines 1-2). Muth fails to teach the following: applying another preconditioning step, creating a vacuum, using nitrogen washes steps and the use of rapamycin. McGowan teaches that preconditioning medical articles is known in the art of ethylene sterilization (col.1, lines 26-27 and lines 36-44). McGowan further teaches that creating a vacuum (col.1, lines 52-64) and applying nitrogen rinses (col.2, lines 12-

14) are also conventional steps in such an art. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to further modify Muth method by including an additional preconditioning step since at elevated temperatures ethylene oxide gas is thought to be more molecularly active and therefore performs more effectively as a sterilizing agent as taught by McGowan (col.1, lines 36-40).

As to the limitation that the drug coated on the medical device comprises a compound that inhibits mTOR and binds FKBP12 in claims 1-20, Muth discloses a method of sterilizing drug coated medical devices; however, it is unclear whether the drugs in Muth include a compound that inhibits mTOR and binds FKBP12. Mitchell teaches it is known in the art to provide drug coated medical devices with a compound such as rapamycin in order to treat patients with vascular disease. The ability of Rapamycin to inhibit mTOR and to bind to FKBP12 is an inherent property as evidenced by the Sigma-Aldrich Internet printout. Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to further modify Muth method by sterilizing a drug coated medical device where the drug includes the compound in order to treat patients with vascular disease and further since rapamycin is known to inhibit transplantation rejection in mammals (page 3, numbered lines 12-13) making organ donations safer for recipients.

Regarding claims 3, 7, 10, 28 and 31, Muth teaches the following: the first predetermined period is three hours (col.6, lines 45-46), removing the sterilant from the packaged drug coated medical device (col.7, table, exhaust) and a biocompatible vehicle or coating that includes an agent in therapeutic dosages (col.8, lines 27-31).

Regarding claims 2, 4-6, 8-9, 21 and 29-30, McGowan teaches the following: reducing the pressure in the chamber to under 10 kPa (col.10, lines 37-45), injecting gaseous ethylene oxide at a concentration from 200-1200 mg/l over a second predetermined period of 6 hours (col.2, lines 5-9), injecting ethylene oxide at a concentration from 800-950 mg/l over a second predetermined period of 6 hours (col.2, lines 5-9), removing the sterilant through a series of alternating vacuum and nitrogen injection stages over a third predetermined period from 2-48 hours (col.2, lines 12-14 and lines 60-65), removing the packaged drug coated medical device from the chamber and positioning it in a controlled environment (col.2, lines 18-22), circulating ambient air (col.2, lines 13-14), maintaining the temperature from 10-70 degrees Celsius (col.2, lines 21-22) over time period from 1 hour-2 weeks (col.2, lines 64-65) or over time period from 12 hours-7 days (col.2, lines 64-65) and placing the packaged drug coated medical device in a preconditioning chamber (col.1, line 27) then maintaining the temperature from 10-70 degrees Celsius (col.1, lines 31-32) and the relative humidity from 20%-95% (col.1, lines 32-33) over a time period of 1 hour-5 days (col.1, lines 34-35).

5. Claims 22-27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Muth et al (U.S.P.N. 5,472,702) in view of McGowan, Jr. (U.S.P.N. 5,749,203), Mitchell (EP 0 568 310) as further evidenced by Sigma-Aldrich (biocompare.com Internet printout) as applied to claim 21 and further in view of Popescu et al (U.S.P.N. 5,464,580).

Regarding claim 22, Muth, McGowan and Mitchell all fail to disclose a temperature range and a time interval as recited in the claim. Both Muth and McGowan

Art Unit: 1744

disclose a relative humidity range value that falls within the recited range, for example, McGowan teaches preconditioning at a relative humidity from 40%-80% (col.1, lines 31-32). Popescu teaches preconditioning at 25 degree Celsius for a time period from 60-90 minutes (col.5, lines 24 and 35-36). Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify Muth method by adjusting the temperature range and the exposure time interval since such modifications is a matter of optimization as evidenced by Popescu.

Claims 23-27 have already been addressed above with respect to claims 2-6.

6. Claims 11-13 and 32-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Muth et al (U.S.P.N. 5,472,702) in view of McGowan, Jr. (U.S.P.N. 5,749,203), Mitchell (EP 0 568 310) as further evidenced by Sigma-Aldrich (biocompare.com Internet printout) as applied to claims 10 and 20 and further in view of Rich (U.S.P.N. 6,025,414) and Pharriss et al (U.S.P.N. 3,675,647).

Regarding claims 11-12 and 32-33, Muth, McGowan and Mitchell all fail to teach using the polymers poly (ethylene-co-vinyl acetate) and polybutylmethacrylate as coating material. Rich teaches that poly (ethylene-co-vinyl acetate) is incorporated into layers of implants (col.3, lines 36-37 and col.4, line 10). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to further modify composition of the medical devices coated in Muth to include the polymer poly (ethylene-co-vinyl acetate) as taught by Rich since it is known for its resiliency (col.4, lines 2-3).

Regarding claims 11-12 and 32-33, Rich fails to teach using the polymer polybutylmethacrylate. Pharriss teaches using polybutylmethacrylate (col.3, line 63). Thus, it would have been obvious to one having ordinary skill in the art at the time the invention was made to further modify composition of the implants in Rich to include the polymer polybutylmethacrylate as taught by Pharriss since it is known to be biologically acceptable flexible, resilient, polymeric material (col.3, lines 59-60).

Regarding claims 13 and 34, Muth teaches incorporating the agent into the first layer (col.8, lines 28-30).

7. Claims 14-19 and 35-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Muth et al (U.S.P.N. 5,472,702) in view of McGowan, Jr. (U.S.P.N. 5,749,203), Mitchell (EP 0 568 310) as further evidenced by Sigma-Aldrich (biocompare.com Internet printout) as applied to claims 10 and 20 and further in view of Gingras (WO 00/38754).

Regarding claims 14-19 and 35-40, Muth, McGowan and Mitchell all fail to teach incorporating polyfluoro copolymers made up of first moiety and second moiety into medicated medical devices. Gingras teaches combining various biocompatible polyfluoro copolymers with polyfluoro monomers (page 10, lines 5-10) in coating layers for stent such that the coating layers are made of first and second moieties that is intrinsically combined in various concentration ranges. Also, Gingras the use of hexafluoropropylene (page 10, line 10). As a result, it would have been obvious to one of ordinary skill in the art at the time the invention was made to further modify composition of the coatings for medical devices in Muth to include hexafluoropropylene

as taught by Gingras since such a compound is known to be biocompatible (page 10, line 5).

Response to Arguments

8. Applicant's arguments filed on 09/09/2006 have been fully considered but they are not persuasive.

On page 12 of the Remarks/Arguments section, Applicant argues that, Muth sterilizes a device coated with protein whereas McGowan sterilizes a device and that McGowan sterilizes by using ethylene-oxide and steam at temperatures higher than the temperature ranges recited in the instant claims. Applicant is referred to page 3 of the action dated 06/20/2006 where temperature ranges recited in the instant claims are taught by Muth. Arguments with respect to temperature ranges utilized by McGowan are irrelevant. As noted by the Applicants, temperature ranges cited by McGowan overlap with the temperature ranges disclosed in the instant claims. In addition, both Muth and McGowan are in the art of sterilizing items with ethylene oxide just like the current disclosure and both are analogous art that do not teach against each other since McGowan is combined with Muth for the preconditioning step, for creating vacuum, for using nitrogen washes and not for the temperature ranges. McGowan teaches that such steps are conventional in the art of ethylene oxide sterilization.

On page 12 of the Remarks/Arguments section, Applicant argues that, "Applicant requires a more specific showing of why all of the references should be combined." Applicant is referred to page 4 of the action dated 06/20/2006 where motivations for combining the references are provided by McGowan and by Mitchell. Furthermore, with

regard to the feature of a compound that inhibits mTOR and binds FkBP12, Mitchell is combined with the Sigma-Aldrich Internet printout to show that Rapamycin does have such inherent properties. Again, the motivation is provided by Mitchell as clearly explained on page 4 of the action dated 06/20/2006. Obviously, the motivation statements are from the prior art of record.

Conclusion

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MONZER R. CHORBAJI whose telephone number is (571) 272-1271. The examiner can normally be reached on M-F 9:00-5:30.
10. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, GLADYS J. CORCORAN can be reached on (571) 272-1214. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
11. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MRC


GLADYS JP CORCORAN
SUPERVISORY PATENT EXAMINER